Fornaro P, Gandini F, Marin M, Pedrazzi C, Piccoli P, Tognetti D, Assael B M, Lucioni C, Mazzi S
Italian Sentinel Group on Pediatric Infectious Diseases, Milan.
Pediatr Infect Dis J. 1999 May;18(5):414-9. doi: 10.1097/00006454-199905000-00004.
Describing the epidemiology of varicella is relevant to the development of specific prevention strategies and to building up of economic models evaluating the cost:efficiency ratios of these strategies.
Our study was designed to describe the epidemiology of chickenpox among Italian children and to assess the resulting economic and health burden on the country.
Thirty-nine Italian pediatricians participated in a sentinel network on pediatric infectious diseases representing a total pediatric population of 30 168 children. Each case of varicella observed from January through December, 1997, was recorded. Economic analysis was conducted from the societal point of view. All costs were broken down into two groups: direct and indirect costs.
A total of 1599 cases of varicella were reported among children 0 to 14 years old. There were 1266 primary cases (mean age, 4.5 +/- 2 years) and 333 secondary cases (mean age, 3.6 +/- 3.2 years). The global incidence of chickenpox was 51.01/1000/year. Complications were seen in 56 cases (3.5%). Drugs were prescribed in 672 cases. A group of adults (364 susceptible and 193 with uncertain status) were exposed to primary cases. Seventy (12.5%) were eventually infected among whom there were 4 pregnant women. For pediatric patients an average cost of $146.90 (250 400 lire) was estimated; this is largely accounted for by indirect costs.
The epidemiology of varicella in Italy is consistent with that found in previous studies in industrialized countries. Severe complications did not occur in our population. We believe that the health arguments in favor of universal vaccination of children > 18 months of age do not differ in our own country from those of other industrialized nations. Our data could now be incorporated into pharmacoeconomic models to establish cost-efficient strategies for Italy.
描述水痘的流行病学情况对于制定特定的预防策略以及构建评估这些策略成本效益比的经济模型具有重要意义。
我们的研究旨在描述意大利儿童水痘的流行病学情况,并评估由此给该国带来的经济和健康负担。
39名意大利儿科医生参与了一个儿科传染病哨点网络,该网络覆盖的儿童总人口为30168名。记录了1997年1月至12月间观察到的每一例水痘病例。从社会角度进行了经济分析。所有成本分为两类:直接成本和间接成本。
在0至14岁的儿童中,共报告了1599例水痘病例。其中有1266例原发病例(平均年龄4.5±2岁)和333例继发病例(平均年龄3.6±3.2岁)。水痘的总体发病率为51.01/1000/年。56例(3.5%)出现了并发症。672例病例开具了药物。一组成年人(364名易感者和193名状态不确定者)接触了原发病例。最终70人(12.5%)被感染,其中有4名孕妇。对于儿科患者,估计平均成本为146.90美元(250400里拉);这主要由间接成本构成。
意大利水痘的流行病学情况与先前在工业化国家的研究结果一致。我们的研究人群中未出现严重并发症。我们认为,支持对18个月以上儿童进行普遍接种疫苗的健康论据在我国与其他工业化国家并无不同。我们的数据现在可纳入药物经济学模型,以制定意大利的成本效益策略。